To investigate whether targeting TREK1 and TREK2 activity would treat migraine, we first verified whether the TREK agonist ML67-33 (Bagriantsev et al., 2013) specifically activated TREK1 and TREK2 channels. The gene discussed is KCNK10; the disease is migraine disorder.